
A breakthrough liquid biopsy test may revolutionize treatment decisions for non-small cell lung cancer (NSCLC) patients with widespread metastatic disease. The test analyzes circulating tumor DNA in blood to determine the extent of cancer spread. Researchers found that patients with low or undetectable levels of ctDNA benefit most from high-dose radiation, experiencing more extended survival periods. This non-invasive approach provides a more precise measure of disease burden, improving personalized treatment decisions for NSCLC patients.
Like
Save
Share